Longest Synthetic Virus Created
News Nov 07, 2016
Gen9, in partnership with Auburn University and Autodesk, announced the successful manufacture of a synthetic viral genome for canine bone cancer research. The sCAV2 virus, measuring over 34,000 base pairs in length, is the longest functional virus synthesized by scientists for oncology research. The sCAV2 virus is a conditionally replicative adenovirus (CRAd), or a class of oncolytic viruses, that selectively targets and destroys tumor cells, avoiding healthy cells in the process.
A team of clinicians and scientists led by Dr. Bruce Smith at Auburn University’s College of Veterinary Medicine will use the synthetic virus in clinical trials to evaluate therapeutic treatments in dogs with osteosarcoma, a type of bone cancer with a survival rate of less than 10%.
“Our concept is taking personalized medicine to precision medicine. The technology to create a new virus by synthesizing it is a huge leap, but the ability to then make a customized virus tailored to the specific needs of each patient will be transformative,” said Bruce F. Smith, V.M.D, Ph.D., Professor, Department of Pathobiology and Director of the Auburn University Research Initiative in Cancer (AURIC). “This could change the way we fight cancer. It is that revolutionary.”
Gen9’s BioFab® DNA synthesis platform was utilized in the synthesis of the sCAV2 oncolytic virus. By leveraging the technology’s ability to manufacture hundreds of megabases of high-quality long-length synthetic DNA, the timeframe for development was reduced from months to weeks, enabling Dr. Smith and his team to drastically accelerate their research. Using a synthetic approach also opens the possibility of the rapid creation of therapeutic viruses tailored to specific patients’ needs.
“The construction of this viral genome is a tremendous step for DNA synthesis and its application to therapeutics research,” said Dr. Devin Leake, Vice President of Research and Development at Gen9. “Our partnership with Autodesk and Auburn sums up what fundamentally excites us the most about the field of synthetic biology and what we do here at Gen9—collaborating with world-class scientists on the groundbreaking research that is shaping the future.”
“At Autodesk, we’ve been prototyping the ‘3D printing’ of medicines for several years,” said Andrew Hessel, distinguished research scientist in the Autodesk BioNano Research Group, and the catalyst behind the project. “This work demonstrates that personalized, made-on-demand therapies are within reach, and our efforts in combatting cancer in dogs could lead the way in next-generation care.”
Story from Gen9. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks’ style and length guidelines.
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018